Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma

Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma Pancreatic adenocarcinoma (PAC) remains one of the most lethal cancers. The overall 5-year survival rate (all stages) remains <5%. Most people present with advanced disease and even the minority who present with resectable disease still, predominantly, die of recurrent metastatic cancer. Adjuvant treatment after surgical resection has been proposed as a method of increasing the cure rate of patients with PAC, but despite developments in new systemic and radiation treatment techniques, the optimal adjuvant therapy, according to the available evidence, is yet to be clearly defined. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma

Loading next page...
 
/lp/springer-journals/evidence-based-adjuvant-treatment-of-resectable-pancreatic-u7s0uDhZdl
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504030-00003
Publisher site
See Article on Publisher Site

Abstract

Pancreatic adenocarcinoma (PAC) remains one of the most lethal cancers. The overall 5-year survival rate (all stages) remains <5%. Most people present with advanced disease and even the minority who present with resectable disease still, predominantly, die of recurrent metastatic cancer. Adjuvant treatment after surgical resection has been proposed as a method of increasing the cure rate of patients with PAC, but despite developments in new systemic and radiation treatment techniques, the optimal adjuvant therapy, according to the available evidence, is yet to be clearly defined.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References